- In April 2025, a study highlighted that Oxymetazoline 1% cream effectively reduces erythema in rosacea patients, particularly those with darker skin tones, by targeting alph adrenoceptors. This topical treatment, initially approved by the US FDA in 2017, continues to be an important option for managing rosacea-associated facial redness, showing efficacy in decreasing redness, stratum corneum hydration, telangiectasia, and vessel diameter
- In February 2025, researchers from the University of Maryland School of Medicine, in a study published in Scientific Reports, described a new skin disease causing erythroderma and successfully treated it with a targeted dual biologic therapy. This breakthrough involved identifying increased levels of interleukin-13 and interleukin-17 in the patient's blood and subsequently using biologic inhibitors (dupilumab and secukinumab) to reverse the disease. This highlights the potential for precision medicine and novel diagnostic tools in treating severe inflammatory skin conditions
- In November 2024, Journey Medical Corporation received FDA approval for DFD-29 (minocycline hydrochloride extended-release capsules, 40mg), now known as Emrosi. This marks a significant advancement as it's the first oral, systemic therapy approved in the US to address both erythema and inflammatory lesions associated with rosacea. This innovative formulation offers steady drug delivery, aiming to reduce adverse effects and improve tolerability for patients
- In November 2022, Arcutis introduced Zoryve in the U.S. market, a development that followed the company's acquisition of treatments for plaque psoriasis. Concurrently, Arcutis released promising late-stage clinical data for its roflumilast foam, specifically indicated for the treatment of moderate-to-severe seborrheic dermatitis in individuals aged nine and older
- In 2021, The "National Rosacea Society" reported 737,960,000 individuals globally affected by rosacea, with 420,280,000 diagnosed. Moreover, approximately 16 million Americans suffer from rosacea, leading to an increasing number of patients seeking medical assistance for facial erythema in clinics and hospitals
